Publications by authors named "Daria Gramenitskaya"
Article Synopsis
- Systemic immune activation, indicated by elevated levels of C-reactive protein (CRP) and interleukin-6 (IL-6), affects immune responses in patients with non-small cell lung cancer (NSCLC) undergoing treatment with immune checkpoint inhibitors (ICIs).
- The study assessed the link between CRP levels, patient outcomes like overall survival (OS) and progression-free survival (PFS), and explored the immune mechanisms associated with these factors.
- Results indicated that patients with high CRP at baseline (CRP-H) had significantly poorer outcomes, including shorter OS and PFS, and that CRP-H was an independent predictor of increased mortality risk and lower disease response rate
Sensitivity to immune checkpoint inhibitor (ICPI) therapy is governed by a complex interplay of tumor and host-related determinants. Epidemiological studies have highlighted that exposure to antibiotic therapy influences the probability of response to ICPI and predict for shorter patient survival across malignancies. Whilst a number of studies have reproducibly documented the detrimental effect of broad-spectrum antibiotics, the immune-biologic mechanisms underlying the association with outcome are poorly understood.
View Article and Find Full Text PDF